BioSpace News Archive

Deals

Autolus Launches Roadshow for Initial Public Offering

Autolus Therapeutics Limited is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies

June 8, 2018
·
4 min read
Business

Autolus Announces Appointment of Linda Bain to its Board of Directors

Effective prior to the closing of Autolus’ planned initial public offering.

June 8, 2018
·
2 min read
Business

Autolus Announces Appointment of Andrew J. Oakley as Senior Vice President and Chief Financial Officer

Effective prior to the closing of Autolus’ planned initial public offering.

June 8, 2018
·
2 min read
Job Trends

Benchmark Electronics Announces Quarterly Cash Dividend

- Second quarter 2018 cash dividend of $0.15 per share

June 8, 2018
·
2 min read
Business

Healthcare Trust of America, Inc. Discusses MOB Same Store Growth and Related Topics

Since becoming a publicly traded company in 2012, HTA’s same store performance has followed a similar pattern, ranging from 2.3% to 3.8% while averaging 3.1%.

June 8, 2018
·
7 min read
Job Trends

iWi® Launches Line of Omega-3s for Planet-based Nutrition

iWi, the brand revolutionizing nutrition with healthy, sustainable, algae-based products, launches nationwide today with a full line of omega-3 supplements and an ad campaign starring Beth Dover of Orange is the New Black.

June 8, 2018
·
2 min read
Job Trends

Healthcare Trust of America, Inc. Announces Stock Repurchase Program

Board of Directors approved a stock repurchase program authorizing the Company to purchase up to $100 million of its Class A common stock from time to time prior to June 7, 2020.

June 8, 2018
·
5 min read
Genetown

Sage Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference

Sage Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders

June 8, 2018
·
1 min read
Drug Development

Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1)

Patients Receiving Investigational Lumasiran Experienced Substantial and Sustained Reductions in Urinary Oxalate, Confirming Potential for RNAi-Mediated Inhibition of Glycolate Oxidase as a Robust Therapeutic Approach for PH1

June 8, 2018
·
11 min read
Biotech Bay

BioTime Announces Submission of Draft Registration Statement for a Proposed Distribution of Its AgeX Shares

Draft registration statement filed on Form 10 with the U.S. Securities and Exchange Commission

June 8, 2018
·
5 min read